Evidence map›Paper›PMID 21736749›Full record

SynthesisBMC medical genomics2011

Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors.

Marla H Daves, Susan G Hilsenbeck, Ching C Lau, Tsz-Kwong Man

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in BMC medical genomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Marla H DavesDan L, Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.
Susan G Hilsenbeck
Ching C Lau
Tsz-Kwong Man
Baylor College of Medicine · USChildren's Cancer Center · US

Funding

PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAMK12CA090433 · NCI · BAYLOR COLLEGE OF MEDICINE · PI CARL E ALLEN, Donald W. Parsons · 2002 to 2026
$18.5M
Diagnostic and Prognostic Sarcoma SignaturesU01CA114757 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI TRICHE, TIMOTHY J. · 2005 to 2009
$8.5M
Genomic Profile-Based Prognostic Markers for EpendymomaR33CA097874 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LAU, CHING CHING · 2004 to 2007
$2.1M
Pediatric Oncology Research Training ProgramT32CA115303 · NCI · BAYLOR COLLEGE OF MEDICINE · PI POPLACK, DAVID G. · 2006 to 2010
$1.5M
NCI NIH HHS K12 CA090433NCI NIH HHS R33 CA97874-05NCI NIH HHS T32 CA115303NCI NIH HHS U01 CA114757-04
6 · The paper itself

Abstract

backgroundMetastasis is the number one cause of cancer deaths. Expression microarrays have been widely used to study metastasis in various types of cancer. We hypothesize that a meta-analysis of publicly available gene expression datasets in various tumor types can identify a signature of metastasis that is common to multiple tumor types. This common signature of metastasis may help us to understand the shared steps in the metastatic process and identify useful biomarkers that could predict metastatic risk.

methodsWe identified 18 publicly available gene expression datasets in the Oncomine database comparing distant metastases to primary tumors in various solid tumors which met our eligibility criteria. We performed a meta-analysis using a modified permutation counting method in order to obtain a common gene signature of metastasis. We then validated this signature in independent datasets using gene set expression comparison analysis with the LS-statistic.

resultsA common metastatic signature of 79 genes was identified in the metastatic lesions compared with primaries with a False Discovery Proportion of less than 0.1. Interestingly, all the genes in the signature, except one, were significantly down-regulated, suggesting that overcoming metastatic suppression may be a key feature common to all metastatic tumors. Pathway analysis of the significant genes showed that the genes were involved in known metastasis-associated pathways, such as integrin signaling, calcium signaling, and VEGF signaling. To validate the signature, we used an additional six expression datasets that were not used in the discovery study. Our results showed that the signature was significantly enriched in four validation sets with p-values less than 0.05.

conclusionsWe have modified a previously published meta-analysis method and identified a common metastatic signature by comparing primary tumors versus metastases in various tumor types. This approach, as well as the gene signature identified, provides important insights to the common metastatic process and a foundation for future discoveries that could have broad application, such as drug discovery, metastasis prediction, and mechanistic studies.

Indexed as

Gene Expression ProfilingDatabases, FactualDisease ProgressionHumansNeoplasm MetastasisOligonucleotide Array Sequence AnalysisVascular Endothelial Growth Factor AVascular Endothelial Growth Factor A

Identifiers

PMID21736749
PMCPMC3212952
OpenAlexW2091309870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.